直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 116538
著者
Kimura, Shun-ichi Jichi Medical University
Kanda, Yoshinobu Jichi Medical University
Iino, Masaki Yamanashi Prefectural Central Hospital
Fukuda, Takahiro National Cancer Center Hospital
Sakaida, Emiko Chiba University
Oyake, Tatsuo Iwate Medical University
Yamaguchi, Hiroki Nippon Medical School
Fujiwara, Shin-ichiro Jichi Medical University
Jo, Yumi Shimane University
Okamoto, Akinao Fujita Health University
Fujita, Hiroyuki Saiseikai Yokohama Nanbu Hospital
Takamatsu, Yasushi Fukuoka University
Saburi, Yoshio Oita Prefectural Hospital
Matsumura, Itaru Kindai University
Yamanouchi, Jun Ehime University
Shiratori, Souichi Hokkaido University
Gotoh, Moritaka Tokyo Medical University
Tamura, Kazuo Fukuoka University
キーワード
Neutropenia
D-index
D-index-guided early antifungal therapy
Empirical antifungal therapy
Micafungin
資料タイプ
学術雑誌論文
抄録
Objectives: The D-index is defined as the area over the neutrophil curve during neutropenia. The CEDMIC trial confirmed the noninferiority of D-index-guided early antifungal therapy (DET) using micafungin to empirical antifungal therapy (EAT). In this study, we evaluated the efficacy and safety of micafungin in these settings.
Methods: From the CEDMIC trial, we extracted 67 and 113 patients who received micafungin in the DET and EAT groups, respectively. Treatment success was defined as the fulfilment of all components of a five-part composite end point. Fever resolution was evaluated at seven days after the completion of therapy.
Results: The proportion of high-risk treatments including induction chemotherapy for acute leukemia and allogeneic hematopoietic stem cell transplantation was significantly higher in the DET group than in the EAT group (82.1% vs. 52.2%). The efficacy of micafungin was 68.7% (95%CI: 56.2–79.4) and 79.6% (71.0–86.6) in the DET and EAT groups, respectively. When we focused on high-risk treatments, the efficacy was 69.1% (55.2–80.9%) and 78.0% (65.3–87.7%), respectively (P = 0.30). There was no significant difference in any of the 5 components between the two groups.
Conclusions: The efficacy of micafungin in patients undergoing high-risk treatment was not strongly impaired in DET compared to that in EAT.
掲載誌名
International Journal of Infectious Diseases
ISSN
12019712
cat書誌ID
AA12791510
出版者
International Society for Infectious Diseases|Elsevier
100
開始ページ
292
終了ページ
297
発行日
2020-09-03
権利情報
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系